Medicare's GLP-1 weight-loss program opens for seniors with guidance
Medicare is rolling out a temporary Bridge program that will cover GLP-1 weight-loss medications (Wegovy, Zepbound, and Foundayo) for eligible adults at about $50 per month, running through December 2027. To qualify, individuals must be 18+ on Medicare Part D and meet BMI criteria (35+ or 27–34.9 with obesity-related conditions). Studies suggest older adults can lose weight as effectively as younger people on these drugs, but data are still limited and side effects, dehydration, and potential muscle loss mean close medical supervision is essential. Recommendations include staying hydrated, seeking nutritional counseling, prioritizing protein to preserve muscle, engaging in resistance exercise, and keeping goals focused on function rather than a specific weight. The program aims to reduce obesity-related health risks and may improve long-term outcomes, though cost and individual risk must be weighed.